Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Tuesday the receipt of US Food and Drug Administration final approval for an Abbreviated New Drug Application for Erlotinib Hydrochloride Tablets (generic Tarceva) in EQ 25mg base, EQ 100mg base and EQ 150mg base strengths for the treatment of non-small cell lung cancer and pancreatic cancer.
The Abbreviated New Drug Application of Erlotinib Hydrochloride Tablets is reportedly held by Natco Pharma Limited and developed in collaboration with MEDIK Ltd.
Under Breckenridge's marketing, sale and distribution agreement, the Erlotinib Hydrochloride Tablets will be manufactured and supplied by Natco and Breckenridge plans to launch the product immediately.
According to industry sales data, Tarceva and its therapeutic equivalents generated annual sales of approximately USD145m in the year ended 30 September 2019.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules